Please use this identifier to cite or link to this item:
|Title:||Trends in the exploration of therapeutic targets for the treatment of endocrine, metabolic and immune disorders||Authors:||Chen, X.
|Issue Date:||Sep-2007||Citation:||Chen, X.,Zheng, C.J.,Han, L.Y.,Xie, B.,Chen, Y.Z. (2007-09). Trends in the exploration of therapeutic targets for the treatment of endocrine, metabolic and immune disorders. Endocrine, Metabolic and Immune Disorders - Drug Targets 7 (3) : 225-231. ScholarBank@NUS Repository. https://doi.org/10.2174/187153007781662576||Abstract:||A number of therapeutic targets have been explored for developing drugs in the treatment of endocrine, metabolic and immune disorders. Continuous efforts and increasing interest have been directed at the search of new targets. Data from the therapeutic target database at http://bidd.nus.edu.sg/group/cjttd/ttd.asp, shows that there are 26, 24, and 22 targets of marketed drugs for the treatment of these three classes of diseases, respectively. The number of targets of investigational agents has reached 98, 124, and 72, respectively. An analysis of these targets, particularly those of recently approved drugs and patented investigational agents, provides useful hint about the general trends of target exploration, with current focus on drag discovery and the difficulties encountered in developing drugs against these targets. Multiple profiles of these targets have been analyzed to probe the sequence, structural, physicochemical and systems-related features contributing to the successful exploration of a target against these diseases. © 2007 Bentham Science Publishers Ltd.||Source Title:||Endocrine, Metabolic and Immune Disorders - Drug Targets||URI:||http://scholarbank.nus.edu.sg/handle/10635/102071||ISSN:||18715303||DOI:||10.2174/187153007781662576|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.